Core Opinion - The audit report indicates that Hunan Yiweidi Medical Equipment Co., Ltd. has prepared its financial statements in accordance with the relevant accounting standards, providing a fair representation of its financial position as of March 31, 2025, and its operating results and cash flows for the first quarter of 2025 [1][3]. Company Overview - Hunan Yiweidi Medical Equipment Co., Ltd. was established in January 2011 and is primarily engaged in the research, development, manufacturing, and sales of medical devices, as well as the production of sanitary materials and medical supplies [3][4]. - The company is controlled by Cheng Zhenghui, who holds 42.34% of the shares [3]. Financial Reporting Basis - The financial statements are prepared based on the "Enterprise Accounting Standards" issued by the Ministry of Finance, with a focus on the going concern assumption [3][4]. - The reporting period for the financial statements is from January 1 to December 31 each year [3]. Important Accounting Policies - The company uses the Chinese Yuan (RMB) as its functional currency and recognizes cash and cash equivalents based on liquidity and risk of value change [3][4]. - Financial instruments are classified at initial recognition based on the business model and cash flow characteristics [4][5]. Financial Assets and Liabilities - Financial assets are classified into categories such as those measured at amortized cost and those measured at fair value, with specific criteria for each category [4][5]. - The company recognizes expected credit losses based on historical data and future economic forecasts, applying a probability-weighted approach [7][8]. Inventory Management - Inventory is classified into categories such as raw materials, finished goods, and work in progress, and is measured at the lower of cost or net realizable value [8][9]. Long-term Investments - Long-term equity investments are accounted for using the equity method, with adjustments made based on the investee's net income and other comprehensive income [10][11]. Fixed Assets and Depreciation - Fixed assets are recognized at cost and depreciated using the straight-line method over their useful lives, which vary by asset type [12][13]. Intangible Assets - Intangible assets are initially measured at cost, with amortization applied to those with finite useful lives [14][15]. Employee Benefits - The company recognizes short-term employee benefits as liabilities and expenses in the period they are incurred, including social insurance and housing fund contributions [18][19].

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-032 深圳惠泰医疗器械股份有限公司 关于调整 2021 年限制性股票激励计划授予价格、授 予及归属数量的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳惠泰医疗器械股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日 召开 2025 年第二次独立董事专门会议、第二届董事会薪酬与考核委员会第七次 会议及第二届董事会第二十三次会议，审议通过了《关于调整 2021 年限制性股 票激励计划授予价格、授予及归属数量的议案》，同意根据《深圳惠泰医疗器械 股份有限公司 2021 年限制性股票激励计划（草案）》（以下简称《激励计划（草 案）》或"本激励计划"）及其摘要的有关规定及公司 2021 年第一次临时股东 大会的授权，对本激励计划的授予价格、授予及归属数量进行调整。现将相关事 项公告如下： 一、本激励计划已履行的决策程序和信息披露情况 （六）2021 年 4 月 26 日，公司召开第一届董事会第十二次会议与第一届监 事会第十次会议，审议通过了《关 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-031 深圳惠泰医疗器械股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳惠泰医疗器械股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日 以现场结合通讯表决方式召开了第二届董事会第二十三次会议，会议应到董事 9 人，实到董事 9 人，出席董事占应出席人数的 100%。本次会议的召集、召开及 表决程序符合《中华人民共和国公司法》等有关法律、行政法规、规范性文件和 《深圳惠泰医疗器械股份有限公司章程》的规定，会议决议合法有效。经与会董 事审议和表决，会议形成决议如下： 一、审议通过《关于公司放弃部分优先购买权、向控股子公司增资构成与 关联方共同投资暨关联交易的议案》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《深 圳惠泰医疗器械股份有限公司关于公司放弃部分优先购买权、向控股子公司增资 构成与关联方共同投资暨关联交易的公告》（公告编号：2025-034）。 董事会表决结果：7 票同意，反对 0 票，弃 ...

Core Points - The average stock price of the Sci-Tech Innovation Board is 30.54 yuan, with 39 stocks priced over 100 yuan, and the highest priced stock is Cambricon at 541.38 yuan [1][2] - Among the stocks priced over 100 yuan, 281 stocks rose while 292 stocks fell today, with an average decline of 0.82% for the hundred-yuan stocks [1][2] - The premium of the hundred-yuan stocks relative to their issue prices averages 327.76%, with the highest premiums seen in Baili Tianheng, Anji Technology, and Hotgen Biotech [1][2] Industry Summary - The hundred-yuan stocks are concentrated in the electronics, pharmaceutical, and computer industries, with 20, 8, and 5 stocks respectively [1] - The net outflow of main funds from the hundred-yuan stocks today totaled 10.84 million yuan, with significant inflows into Cambricon, United Imaging, and Haiguang Information [2] - The total margin balance for hundred-yuan stocks is 26.32 billion yuan, with Cambricon, Haiguang Information, and Zhongwei Company having the highest margin balances [2]

Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the **domestic medical device industry**, highlighting advancements in various companies and their innovative products. Key Companies and Their Innovations 1. **Peijia Medical** - The shockwave balloon technology shows a **30%-50% efficacy** in early clinical trials for treating aortic valve calcification [1] - The transcatheter aortic valve replacement product **Mona Q** has enrolled **9 patients** in the global Fame clinical trial, with no deaths or strokes reported during long-term follow-up. It has received **IDE clinical approval** in the U.S. and is expected to advance to U.S. clinical trials within the year [2][4] 2. **Jianxi Technology** - The tricuspid valve replacement product has completed clinical registration trials in Europe with a **97% success rate** and is expected to receive CE certification by **2025** [1][3] 3. **Xenon Medical** - The self-expanding intracranial drug-eluting stent has a **restenosis rate of only 1.7%-1.87%** and a **100% surgical success rate**. Approval is anticipated this year, with a market exclusivity period of **1.5 to 2 years** [1][6][7] 4. **HeartTech Medical** - Leading market share in domestic occluder products with a series of **four generations of biodegradable occluders**. The aortic valve product has been approved for commercialization since Q1 [1][8] 5. **Qiming Medical** - Four TAVI products have been approved and marketed in over **ten countries**. New TAVI products are under development, with expectations for a tricuspid valve replacement product to be approved in Europe by **2027** [1][9] Market Trends and Future Outlook - The medical device sector is expected to see a **catalyst for growth** in the second half of the year due to potential equipment upgrades, particularly in **3.0T MRI and 64-slice CT** products [2][17] - Companies like **Huitai Medical** are projected to have strong performance due to new product launches and market expansion [11][23] Competitive Strategies - Domestic medical device companies are enhancing their international competitiveness through: - **Patent breakthroughs** and early clinical trials [4] - Focusing on less crowded market segments for differentiation [4] - Collaborations with international firms to leverage global networks for faster commercialization [5] Financial Performance Expectations - Companies such as **Huitai Medical** and **Mingrui Medical** are expected to show strong growth in the second half of the year, despite some companies facing short-term pressures due to high bases from previous years [10][11][15] - The **IVD sector** is experiencing pressure from policy changes, but improvements are anticipated in the latter half of the year as companies adjust pricing strategies [28] Regulatory and Policy Impact - The medical industry is facing challenges from **DRG cost control policies** and increased compliance requirements, impacting overall performance and cash flow [33] Conclusion - The domestic medical device industry is poised for growth with innovative products and strategic collaborations, despite facing regulatory challenges and market competition. Companies are actively seeking to enhance their international presence and capitalize on emerging market opportunities.

Core Viewpoint - The performance of the CSI All Index for Medical Care Equipment and Services has shown mixed results, with a slight increase on the day but a decline over the past month, three months, and year-to-date [1]. Group 1: Index Performance - The CSI All Index for Medical Care Equipment and Services rose by 0.21% to 13,548.3 points, with a trading volume of 19.92 billion [1]. - Over the past month, the index has decreased by 1.41%, by 2.78% over the past three months, and by 1.24% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the medical care sector, reflecting the overall performance of these securities [1]. - The index was established on December 31, 2004, with a base point of 1,000.0 [1]. Group 3: Top Holdings - The top ten holdings in the index are as follows: Mindray Medical (9.65%), United Imaging (8.18%), Aier Eye Hospital (7.43%), Aimeike (3.42%), Huatai Medical (3.23%), Yuyue Medical (2.81%), New Industry (2.79%), Lepu Medical (2.69%), Meinian Onehealth (2.06%), and Shandong Pharmaceutical Glass (1.9%) [1]. Group 4: Market Distribution - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.10%) and the Shanghai Stock Exchange (39.90%) [1]. - The entire sample of the index is focused on the pharmaceutical and healthcare sector, with a 100% allocation [1]. Group 5: Index Adjustment and Fund Tracking - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. - Public funds tracking the index include various Southern and Tianhong funds, as well as ETFs from multiple asset management companies [2].

惠泰医疗 20250703 摘要 Q&A PFA 技术在房产领域的推广情况如何？ 根据波士顿科学披露的数据，2024 财年内其 PFA 系统全年销售收入超过 10 亿美元，带动其电生理板块收入同比增长接近 140%。国内市场方面，惠泰医 疗的 PFA 系统预计在 2024 年底上市。根据深度报告测算，国内长期空间预计 有超百亿元的远期市场。国产产品较外资有一定差异化优势，今年（2025 年）PFA 有望显著拉动惠泰医疗的业绩。 PFA 技术与传统射频和冷冻消融相比有哪些优势？ 全球房产销售市场及脉冲场消融的发展前景如何？ 惠泰医疗 PFA 产品于 2024 年底获批上市，国产产品在全麻、压力感知、 3D 标测等方面具备差异化优势，更贴近国内医生临床习惯，有望实现对 外资厂商的弯道超车，并显著改变国内电生理行业格局。 PFA 技术通过高压电脉冲诱导心肌细胞死亡，具有组织选择性高、安全 性好、无需热能等优点，且对导管贴靠要求低，缩短手术时间，降低术 式经验要求，有望替代射频和冷冻消融，推动市场扩容。 波士顿科学公司在 PFA 领域先行，2024 年初美国区域快速推广后，公 司股价全年上涨 55%，总市值达到 1, ...

商保创新药目录呼之欲出，内需市场有望迎来明显改善，持续推荐创新药及产业链。 投资要点： 利好不断，持续推荐创新药及产业链 [Table_Industry] 医药 ——HTI 医药 2025 年 7 月月报 [Table_subIndustry] 细分行业评级 本报告导读： 请务必阅读正文之后的免责条款部分 股 票 行 研 究 报 告 股票研究 /[Table_Date] 2025.07.02 [Table_Invest] 业 月 报 证 券 研 究 [table_Authors] 2025-07-03 [Table_Summary] 利好不断，持续推荐创新药及产业链。维持以下 A 股标的优于大市 评级并将其纳入 HTI 医药 2025 年 7 月月度组合：恒瑞医药、科伦药 业、华东医药、药明康德、凯莱英、泰格医药、惠泰医疗。维持以 下 H 股标的优于大市评级：科伦博泰生物、翰森制药、信达生物、 药明合联、映恩生物、百济神州，相关标的：药明康德、康哲药业。 商保创新药目录呼之欲出，内需市场有望迎来明显改善。经国务院 同意，7 月 1 日国家医保局、国家卫健委联合发布《支持创新药高 质量发展的若干措施》，重点提出 ...

Core Insights - The average stock price of the Sci-Tech Innovation Board is 30.77 yuan, with 39 stocks priced over 100 yuan, the highest being Cambricon at 547.30 yuan [1][2] - A total of 365 stocks increased in price today, while 208 stocks decreased, with the average increase for stocks over 100 yuan being 0.34% [1][2] - The average premium of stocks over their issue price for those priced over 100 yuan is 327.13%, with notable premiums for companies like Anji Technology and Baile Tianheng [1][2] Stock Performance - Cambricon closed at 547.30 yuan, up 0.40%, followed by Baile Tianheng at 298.00 yuan and Huitai Medical at 294.38 yuan [1][2] - Among the stocks priced over 100 yuan, 23 stocks increased, with the largest gainers being Hotgen Biotech, Zexin Pharmaceutical, and Naxin Micro [1][2] - The stocks with the largest declines included Longxin Technology, Sirepu, and Zhongke Lanyun [1][2] Industry Distribution - The stocks priced over 100 yuan are concentrated in the electronics, pharmaceutical, and computer industries, with 20, 8, and 5 stocks respectively [1][2] - The total net outflow of main funds from stocks priced over 100 yuan today was 5.46 billion yuan, with notable inflows into companies like Siterui and Zexin Pharmaceutical [2] - The total financing balance for stocks priced over 100 yuan is 26.624 billion yuan, with Cambricon leading at 4.478 billion yuan [2][3]

Company Overview - Shenzhen Huatai Medical Devices Co., Ltd. specializes in the research, production, and sales of electrophysiological and interventional medical devices [1] - The main products include electrophysiological devices, coronary access devices, peripheral vascular interventional devices, and non-vascular interventional medical devices [1] Financial Performance - For Q1 2025, the company reported revenue of 564 million yuan, representing a year-on-year increase of 23.93% [1] - The net profit for the same period was 183 million yuan, showing a year-on-year growth of 30.69% [1] - The gross profit margin stood at 73.09% [1] Market Position - As of July 1, the company's stock closed at 304.5 yuan, with a price increase of 2.53% [1] - The rolling price-to-earnings (PE) ratio reached 59.96 times, while the average PE ratio for the medical device industry is 51.70 times [1][2] - The total market capitalization of the company is 42.939 billion yuan [1] Institutional Holdings - As of Q1 2025, a total of 109 institutions hold shares in Huatai Medical, including 106 funds and 3 other entities, with a total holding of 47.1568 million shares valued at 18.264 billion yuan [1]